Sirio Pharma (300791) — Capital Reinvestment Ratio
Sirio Pharma (300791) has a Capital Reinvestment Ratio of 0.59x as of June 2023, meaning it reinvests 1% of its operating cash flow (CN¥101.61 Million) in capital expenditures (CN¥59.65 Million). Check tangible equity quality of Sirio Pharma to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Sirio Pharma Capital Reinvestment Ratio (2017–2024)
This chart tracks Sirio Pharma's Capital Reinvestment Ratio across 8 annual periods. For the full cash flow conversion analysis, see Sirio Pharma (300791) cash flow conversion.
Annual Capital Reinvestment Ratio for Sirio Pharma (2017–2024)
Year-by-year Capital Reinvestment Ratio for Sirio Pharma from 2017 to 2024. See Sirio Pharma (300791) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.73x | CN¥566.97 Million | CN¥412.13 Million | ▼ -37.9% |
| 2023 | 1.17x | CN¥386.08 Million | CN¥451.70 Million | ▲ +77.2% |
| 2022 | 0.66x | CN¥444.86 Million | CN¥293.69 Million | ▼ -57.0% |
| 2021 | 1.54x | CN¥341.38 Million | CN¥524.68 Million | ▲ +120.1% |
| 2020 | 0.70x | CN¥319.57 Million | CN¥223.14 Million | ▼ -3.1% |
| 2019 | 0.72x | CN¥231.60 Million | CN¥166.90 Million | ▼ -44.8% |
| 2018 | 1.30x | CN¥183.46 Million | CN¥239.32 Million | ▼ -59.7% |
| 2017 | 3.24x | CN¥49.35 Million | CN¥159.82 Million | — |